FDA Determines Regulatory Review Period for OPTIMIZER Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has published a notice determining the regulatory review period for OPTIMIZER, a medical device patent extension, following submissions to the U.S. Patent and Trademark Office (USPTO).